Ligand Pharma (LGND) Issues FY13 Outlook into Analyst Day
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $72.47 -0.07%
Revenue Growth %: -39.3%
Financial Fact:
Income tax expense (benefit): -160K
Today's EPS Names:
MAXN, CSTR, ACU, More
Revenue Growth %: -39.3%
Financial Fact:
Income tax expense (benefit): -160K
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will be providing a detailed review of its business model and growth strategy, along with introducing financial guidance for 2013 and 2014, during its Analyst Day event being held today in New York City.
Chief Executive Officer John Higgins plans to highlight the success of Ligand’s “Shots-on-Goal” business model, reviewing the company’s significant expansion of its partnered portfolio from a total of nine programs several years ago to 70 programs today. He will detail how its current partnered portfolio could result in as many as six new drug launches over the next three years, which would double the number of products generating royalty revenue for Ligand.
Mr. Higgins will also highlight that Ligand is at an inflection point for financial growth as a result of the recent approvals of key partnered products, including Promacta® and Kyprolis™. Ligand’s efficient operating model is projected to generate significant cash flow, which Ligand plans to use for acquisitions to continue building its asset portfolio, or to return capital to shareholders through share repurchases and dividends.
Ligand’s financial forecast includes the following:
* Revenue in 2013 is projected to be between $41 million and $44 million, and is projected to grow to more than $60 million in 2014, representing a 40% compound annual growth rate from 2012 expected revenue of $30 million to $31 million.
* Net income in 2013 is projected to be more than $0.35 per diluted share, and is projected to increase by 200% to more than $1.05 per diluted share in 2014.
* Income per diluted share from discontinued operations in 2012 is expected to be $0.18, and Ligand projects a loss per share from continuing operations for the year of between $0.09 and $0.13.
*** The Street sees FY13 revs of $45 million and EPS of 43 cents. The Street also sees FY12 EPS of 13 cents.
John Sharp, Ligand’s Chief Financial Officer, will provide a detailed analysis of Ligand’s more than $500 million in tax assets, which include net operating loss carryforwards, tax credits and future tax deductions. As a result of these tax assets, Ligand’s actual tax payments are expected to be less than 2% of pre-tax income from 2013 through 2017.
Ligand’s Chief Operating Officer Matt Foehr will discuss Ligand’s research and development model, highlighting the ability of Captisol® to serve as a platform for growth due to the pharmaceutical industry’s increasing need for formulation solubility and stability, and illustrating that:
* Captisol can make new drugs possible, and can make existing drugs better, by enhancing their delivery characteristics.
* Ligand's Captisol-based royalties are well positioned for growth with the recent approval of Kyprolis, and potential new products like The Medicines Company’s MDCO-157 (Captisol-enabled clopidogrel), Lundbeck's carbemazepine, and Rib-X's delafloxacin advancing through or toward late-stage development.
Vice President of Corporate Development Nishan de Silva, M.D. will present an in-depth presentation of select portfolio assets with highlights as follows:
* Ligand is entitled to royalties on Merck’s lead BACE inhibitor compound for Alzheimer’s disease. Merck has reported single doses are associated with up to a 92% mean reduction of beta amyloid levels from baseline. Merck announced the initiation of a Phase 2/3 clinical trial on December 3rd.
* Ligand is entitled to milestones and royalties for dinaciclib, for which Merck recently initiated a Phase 2b/3 study for chronic lymphocytic leukemia.
* Pfizer expects a decision from the European Medicines Agency in 2013 regarding Aprela for the treatment of symptoms associated with menopause and the prevention of osteoporosis.
* Ligand is initiating a pivotal trial for Captisol-enabled melphalan (LGD-353) for the treatment of multiple myeloma.
* GlaxoSmithKline recently received approval for Promacta treatment of thrombocytopenia in patients with chronic hepatitis C and is pursuing development for Promacta in oncology-related indications.
Chief Executive Officer John Higgins plans to highlight the success of Ligand’s “Shots-on-Goal” business model, reviewing the company’s significant expansion of its partnered portfolio from a total of nine programs several years ago to 70 programs today. He will detail how its current partnered portfolio could result in as many as six new drug launches over the next three years, which would double the number of products generating royalty revenue for Ligand.
Mr. Higgins will also highlight that Ligand is at an inflection point for financial growth as a result of the recent approvals of key partnered products, including Promacta® and Kyprolis™. Ligand’s efficient operating model is projected to generate significant cash flow, which Ligand plans to use for acquisitions to continue building its asset portfolio, or to return capital to shareholders through share repurchases and dividends.
Ligand’s financial forecast includes the following:
* Revenue in 2013 is projected to be between $41 million and $44 million, and is projected to grow to more than $60 million in 2014, representing a 40% compound annual growth rate from 2012 expected revenue of $30 million to $31 million.
* Net income in 2013 is projected to be more than $0.35 per diluted share, and is projected to increase by 200% to more than $1.05 per diluted share in 2014.
* Income per diluted share from discontinued operations in 2012 is expected to be $0.18, and Ligand projects a loss per share from continuing operations for the year of between $0.09 and $0.13.
*** The Street sees FY13 revs of $45 million and EPS of 43 cents. The Street also sees FY12 EPS of 13 cents.
John Sharp, Ligand’s Chief Financial Officer, will provide a detailed analysis of Ligand’s more than $500 million in tax assets, which include net operating loss carryforwards, tax credits and future tax deductions. As a result of these tax assets, Ligand’s actual tax payments are expected to be less than 2% of pre-tax income from 2013 through 2017.
Ligand’s Chief Operating Officer Matt Foehr will discuss Ligand’s research and development model, highlighting the ability of Captisol® to serve as a platform for growth due to the pharmaceutical industry’s increasing need for formulation solubility and stability, and illustrating that:
* Captisol can make new drugs possible, and can make existing drugs better, by enhancing their delivery characteristics.
* Ligand's Captisol-based royalties are well positioned for growth with the recent approval of Kyprolis, and potential new products like The Medicines Company’s MDCO-157 (Captisol-enabled clopidogrel), Lundbeck's carbemazepine, and Rib-X's delafloxacin advancing through or toward late-stage development.
Vice President of Corporate Development Nishan de Silva, M.D. will present an in-depth presentation of select portfolio assets with highlights as follows:
* Ligand is entitled to royalties on Merck’s lead BACE inhibitor compound for Alzheimer’s disease. Merck has reported single doses are associated with up to a 92% mean reduction of beta amyloid levels from baseline. Merck announced the initiation of a Phase 2/3 clinical trial on December 3rd.
* Ligand is entitled to milestones and royalties for dinaciclib, for which Merck recently initiated a Phase 2b/3 study for chronic lymphocytic leukemia.
* Pfizer expects a decision from the European Medicines Agency in 2013 regarding Aprela for the treatment of symptoms associated with menopause and the prevention of osteoporosis.
* Ligand is initiating a pivotal trial for Captisol-enabled melphalan (LGD-353) for the treatment of multiple myeloma.
* GlaxoSmithKline recently received approval for Promacta treatment of thrombocytopenia in patients with chronic hepatitis C and is pursuing development for Promacta in oncology-related indications.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- Schlumberger (SLB) earnings in-line, revenue beats expectations
- Barrick Gold (GOLD) reported preliminary Q1 production of 940 thousand ounces of gold
Create E-mail Alert Related Categories
Guidance, Hot GuidanceRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
